Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOKYO.L Regulatory News (OKYO)

  • There is currently no data for OKYO

Corporate Update

21 Aug 2015 16:37

RNS Number : 8013W
West African Minerals Corporation
21 August 2015
 

21 August 2015

For immediate release  

West African Minerals Corporation

("WAFM" or the "Company")

Disposal of Sierra Leone licence interests

On 27 February 2015 the Board of WAFM announced that it had implemented a new stream-lined budget for the Company for 2015 (the "2015 Budget") to reduce expenditure at the operational and corporate level, including the proposal that the Company relinquish its licences in Sierra Leone thereby reducing costs in Sierra Leone to US$50,000 in the 2015 Budget for rehabilitation and wind-up.

The Company has completed its withdrawal from Sierra Leone, which has been effected by the sale on 19 August 2015 of its entire interest in the share capital of its wholly-owned subsidiary, Ferrous Africa Limited ("FAL"). FAL's subsidiaries ("FAL Group") held the Company's five licence interests in Sierra Leone. As a consequence of the disposal, the buyer (Sierra Resources Limited) will be responsible for any liabilities of the FAL Group from completion, including any costs for rehabilitation and wind-up, which had otherwise been estimated to cost the Company US$50,000 in 2015. In addition, the buyer has paid a nominal consideration of US$1. Following completion, the Company has no further interests in Sierra Leone and no further financial liabilities in respect of the Sierra Leone licences.

As set out in the Company's unaudited interim results for the six months ended 30 September 2014, the balance sheet carrying value of the FAL Group as at that date amounted to £4,101,164 (comprising the carrying costs of the Sierra Leone exploration licences of £2,371,151 and capitalised deferred exploration expenditure of £1,730,013) and which will be written down to zero. As at 30 September 2014, Group total assets (before any provision in respect of the FAL Group) amounted to £27,759,163. In the year ended 31 March 2014, audited loss before tax of the FAL Group amounted to £321,497.

For further information contact:

West African Minerals Corporation

Anton Mauve

 

+44 (0) 1624 639396

 

Beaumont Cornish Limited (Nominated Adviser)

Roland Cornish

Michael Cornish

 

+44 (0)20 7628 3396

SP Angel Corporate Finance LLP (Broker)

Ewan Leggat/Katy Birkin

 

+44 (0) 20 3470 0500

ENDS

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBUGDILXDBGUB
Date   Source Headline
19th May 20238:00 amRNSADS Program collapse
15th May 20237:00 amRNSChange of Record Time and Last Day of Dealings
11th May 202312:00 pmRNSWebull Corporate Communications Service Platform
11th May 20237:00 amRNSChange of Delisting Date to 22 May 2023
3rd May 20231:00 pmRNSResult of Meeting
3rd May 20237:00 amRNSPresentation on OK-101 at ASCRS
2nd May 20237:00 amRNSFirst-Patient First-Visit for Phase 2 Trial
25th Apr 20237:00 amRNSActivation of First Clinical Trial Site in the U.S
5th Apr 20237:00 amRNSNOTICE OF GENERAL MEETING AND CIRCULAR PUBLICATION
4th Apr 20237:00 amRNSNotice Of Intention To Delist From The LSE
30th Mar 20237:00 amRNSDirector Acquires Shares
29th Mar 20237:00 amRNSDirector acquires shares
24th Mar 20237:00 amRNSDirector/PDMR Shareholding
16th Mar 20237:01 amRNSListing of Trial on the ClinicalTrials.gov Website
16th Mar 20237:00 amRNSClosing of Global Private Placement
15th Mar 20237:01 amRNSDirector/PDMR Dealings
14th Mar 20237:00 amRNSIssue of Equity
13th Mar 20233:16 pmRNSCEO Interview
6th Mar 20232:00 pmRNSPrice Monitoring Extension
28th Feb 20237:00 amRNSCustom Clearance of GMP Packaged OK-101 Drug
23rd Feb 20237:00 amRNSAppointment to Scientific Advisory Board
21st Feb 20237:00 amRNSCorporate Presentation
20th Feb 20234:35 pmRNSPrice Monitoring Extension
20th Feb 20232:05 pmRNSSecond Price Monitoring Extn
20th Feb 20232:00 pmRNSPrice Monitoring Extension
20th Feb 202311:05 amRNSSecond Price Monitoring Extn
20th Feb 202311:00 amRNSPrice Monitoring Extension
20th Feb 20239:05 amRNSSecond Price Monitoring Extn
20th Feb 20239:00 amRNSPrice Monitoring Extension
17th Feb 20234:40 pmRNSSecond Price Monitoring Extn
17th Feb 20234:35 pmRNSPrice Monitoring Extension
14th Feb 20237:00 amRNSAllotment of Shares and Total Voting Rights
10th Jan 20234:40 pmRNSSecond Price Monitoring Extn
10th Jan 20234:35 pmRNSPrice Monitoring Extension
10th Jan 20232:05 pmRNSSecond Price Monitoring Extn
10th Jan 20232:00 pmRNSPrice Monitoring Extension
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20232:05 pmRNSSecond Price Monitoring Extn
9th Jan 20232:00 pmRNSPrice Monitoring Extension
3rd Jan 20231:15 pmRNSInterim Results - availability
30th Dec 20227:00 amRNSInterim Results for the Six Months Ending 30Sept22
22nd Dec 20227:00 amRNSU.S. FDA Clearance of IND Application for OK-101
21st Dec 20227:00 amRNSOKYO to Participate at Biotech Showcase
6th Dec 20227:00 amRNSOKYO files a registration statement with the SEC
1st Dec 20227:00 amRNSChange of Auditor
24th Nov 20227:00 amRNSDirector/PDMR Shareholding
21st Nov 20227:00 amRNSU.S. IND Filing on OK-101 for the Treatment of DED
20th Oct 20227:00 amRNSOKYO to participate at 2022 ThinkEquity Conference
8th Sep 20222:30 pmRNSOKYO interview on Bloomberg: RedChip Money Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.